Nanomillions in nine months
JSC RUSNANO has published the results of its activities for 9 months of 2011
The company's revenue for the period from 11.03.2011, when JSC RUSNANO was created through the reorganization of the Rosnanotech Group, amounted to 1.7 billion rubles by 30.09.2011. (for the period from 11.03. to 30.06.2011 – 918 million rubles.).
The loss for 9 months of 2011 amounted to 2.1 billion rubles. (for the period from 11.03. to 30.06.2011 – 1.2 billion rubles.). It is due to the payment of interest on the funds raised to finance projects in which RUSNANO participates. In accordance with the financing scheme, RUSNANO will receive profit from investments through the sale of its shares in project companies, as well as from the payment of dividends by project companies.
For 9 months of 2011, RUSNANO's management bodies approved 30 projects with a total budget of 174 billion rubles, including co-financing from RUSNANO in the amount of 59 billion rubles.
In total, as of 01.10.2011, 2,052 requests for project financing were registered, of which 128 projects with a total budget of 501 billion rubles were approved for financing. RUSNANO's share is 213 billion rubles.
68 projects have already been financed: by RUSNANO – for 86 billion rubles, by co–investors - 75.5 billion rubles. At the moment, RUSNANO has financed 4 funds in the amount of 10.0 billion rubles. For 9 months of 2011, they invested about 147 million rubles in various projects.
Distribution of approved projects by applicant countries and by industryAmong the largest investment agreements signed in the third quarter of 2011, medicine and biotechnology include:
Development of renewable fuel production technology developed by Joule Unlimited. RUSNANO's total investment in the project will amount to $35 million. RUSNANO's funds will be used to improve the technology, as well as to organize a research and development center in Russia within the framework of Joule's international development.
Development of a number of promising biomedical drugs, starting from the stage of preclinical studies. RUSNANO will invest up to $26 million over four years in Panacela Labs, a new division of Cleveland BioLabs, Inc. RUSNANO's initial investment will amount to $9 million.
Participation in the Burrill Capital Fund IV investment venture fund. The Fund is created for a period of ten years with a five-year investment period. The funds will be invested in medical and biotechnological projects mainly at the middle stage of development. Priority will be given to investments in companies focused on the development and development of innovative medicines, diagnostic medical equipment, medical and industrial biotechnologies. The maximum investment volume of RUSNANO for this period is up to $ 200 million.
Portal "Eternal youth" http://vechnayamolodost.ru according to the materials of the RUSNANO press service15.11.2011